Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss. From celebrity headlines to everyday conversations, GLP-1 drugs like Ozempic and Wegovy are often framed as breakthroughs ...
May 4, 2026
0
76
Being overweight may lead to accelerated cognitive decline, according to new research from the University of Georgia. The paper is published in the Journal of Neurology.
May 4, 2026
0
8
Inconsistent use of some GLP-1 weight-loss medications, like Ozempic and Wegovy, may significantly lessen their effectiveness, according to a new preclinical study from researchers at the Perelman School of Medicine at the ...
May 3, 2026
0
9
A new study from the University of St Andrews suggests weight-loss drugs like Ozempic taken around pregnancy do not raise the risk of major birth defects. Published in the American Journal of Obstetrics and Gynaecology, the ...
May 2, 2026
0
18
Consumption of ultra-processed foods—including soft drinks, snacks and ready meals—is growing worldwide, despite evidence they are unhealthy.
May 1, 2026
0
7
Weight-related teasing from family members is common among adolescents, and new research from UConn's Rudd Center for Food Policy & Health shows that who the teasing comes from may play an important role in youth health and ...
May 1, 2026
0
2
The study, published in Nature Medicine, shows that future risk of 18 obesity-related diseases can be predicted using 20 commonly collected health measures, such as blood test results and demographic information. The tool ...
Apr 30, 2026
0
9
A new randomized clinical trial provides some of the clearest evidence to date that what we eat can meaningfully reshape both human health and the health of the planet. Researchers have found that a low-fat vegan diet reduced ...
Apr 30, 2026
0
13
New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes, and premature death over a sustained period of time. Researchers from Anglia Ruskin University (ARU) analyzed data from ...
Apr 30, 2026
0
10
A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP signaling pathway as a "door ...
Apr 29, 2026
0
16
